{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:04:13Z","timestamp":1793732653425,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bioorg.2020.103797","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T19:45:20Z","timestamp":1585597520000},"page":"103797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity"],"prefix":"10.1016","volume":"99","author":[{"given":"Tarek S.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghreed A.","family":"Sheha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader E.","family":"Abo-Dya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"AlAwadh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil A.","family":"Alhakamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria K.","family":"Abdel-Samii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva S.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal El-Din A.","family":"Abuo-Rahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh F.A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.103797_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bioorg.2018.06.003","article-title":"Novel pyrrol-2(3H)-ones and pyridazin-3(2H)-ones carrying quinoline scaffold as anti-proliferative tubulin polymerization inhibitors","volume":"80","author":"Abdelbaset","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bioorg.2017.03.005","article-title":"Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors","volume":"72","author":"Mohamed","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0015","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilidehydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2020.103797_b0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacteriumviolaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity","volume":"47","author":"Ueda","year":"1994","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bioorg.2020.103797_b0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2020.103797_b0030","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2020.103797_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2013.03.059","article-title":"Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells","volume":"434","author":"RenQiao","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2020.103797_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Mohammed","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bioorg.2019.103127","article-title":"Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors","volume":"91","author":"Mohamed","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/ml300366t","article-title":"Development of N-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap group","volume":"4","author":"Zhang","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.103797_b0055","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/DDDT.S237957","article-title":"Design, synthesis and biological evaluation of new HDAC1 and HDAC2 inhibitors endowed with ligustrazine as a novel cap moiety","volume":"14","author":"Al-Sanea","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2020.103797_b0060","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/acs.jmedchem.5b01342","article-title":"Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jm301254q","article-title":"Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells","volume":"56","author":"Marek","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0070","doi-asserted-by":"crossref","unstructured":"K. Stenzel, A. Chakrabarti, J. Melesina, F.K. Hansen, J. Lancelot J, S. Herkenh\u00f6hner, B. Lungerich B (1), M. Marek, C. Romier, R.J. Pierce, W. Sippl, M. Jung, T. Kurz, Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni, Arch. Pharm. (Weinheim), 350 (2017) 10.1002\/ardp.201700096.","DOI":"10.1002\/ardp.201700096"},{"key":"10.1016\/j.bioorg.2020.103797_b0075","doi-asserted-by":"crossref","unstructured":"F. Wang F, W. Lu, T. Zhang, J. Dong, H. Gao, P. Li, S.Wang, J. Zhang, Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors. Bioorg. Med. Chem., 21 (2013) 6973\u20136980.","DOI":"10.1016\/j.bmc.2013.09.021"},{"key":"10.1016\/j.bioorg.2020.103797_b0080","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.chembiol.2015.03.014","article-title":"Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via an HDAC-independent catalase-like mechanism","volume":"22","author":"Olson","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2020.103797_b0085","doi-asserted-by":"crossref","unstructured":"F. Yang, T. Zhang, H. Wu H, Y. Yang, N. Liu, A. Chen, Q. Li, J. Li, L. Qin, B. Jiang, X. Wang, X. Pang, Z. Yi, M. Liu, Y. Chen, Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis, J. Med. Chem., 57 (2014) 9357\u20139369.","DOI":"10.1021\/jm5012148"},{"key":"10.1016\/j.bioorg.2020.103797_b0090","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: a med. chem. toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cmdc.200800461","article-title":"Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors","volume":"4","author":"Chen","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2020.103797_b0100","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/jm701079h","article-title":"Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity","volume":"50","author":"Moradei","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0105","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/ml500170r","article-title":"Modulation of activity profiles for largazole-based HDAC inhibitors through alteration of prodrug properties","volume":"5","author":"Salvador","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.103797_b0110","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1021\/jm5008209","article-title":"ST7612AA1, a thioacetate-\u03c9 (\u03b3-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors","volume":"57","author":"Giannini","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0115","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2174\/156802610792232079","article-title":"Macrocyclic histone deacetylase inhibitors","volume":"10","author":"Mwakwari","year":"2010","journal-title":"Curr. Topics Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0120","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1016\/j.bmcl.2004.03.063","article-title":"Thiol-based SAHA analogues as potent histone deacetylase inhibitors","volume":"14","author":"Suzuki","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.103797_b0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of HDAC inhibitors with benzoyl hydrazide scaffold that selectively inhibit Class I HDACs","volume":"22","author":"Wang","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2020.103797_b0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejmech.2018.02.011","article-title":"Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes","volume":"148","author":"Farag","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0135","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing Class I histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.bioorg.2020.103797_b0145","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.bcp.2005.02.012","article-title":"Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives","volume":"69","author":"Eyal","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2020.103797_b0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cmdc.201200585","article-title":"Carboxylic acid (bio)isosteres in drug design","volume":"8","author":"Ballatore","year":"2013","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0160","doi-asserted-by":"crossref","unstructured":"B.G.M. Youssif, M.F.A. Mohamed, M.M. Al-Sanea, A.H. Moustafa, A.A. Abdelhamid, H.A M. Gomaa, Novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles analogues of naproxen as dual selective COX-2 \/ 15-LOX inhibitors: Design, synthesis and Docking studies. Bioorg. Chem. 85 (2019) 577\u2013584.","DOI":"10.1016\/j.bioorg.2019.02.043"},{"key":"10.1016\/j.bioorg.2020.103797_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.bioorg.2020.103797_b0170","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1359-6446(03)02831-9","article-title":"A 'rule of three' for fragment-based lead discovery?","volume":"8","author":"Congreve","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2020.103797_b0175","first-page":"43","article-title":"Amino acyl benzotriazolides: Versatile reagents for the preparation of peptides and their mimetics and conjugates","volume":"46","author":"Panda","year":"2013","journal-title":"Aldrichimica Acta"},{"key":"10.1016\/j.bioorg.2020.103797_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102997","article-title":"EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules","volume":"89","author":"Abou-Zied","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejmech.2017.06.023","article-title":"Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells","volume":"138","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0190","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1021\/acs.jmedchem.6b01846","article-title":"Design, synthesis, and biological evaluation of mitochondria-targeted flavone-naphthalimide-polyamine conjugates with antimetastatic activity","volume":"60","author":"Dai","year":"2017","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2020.103797_b0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejmech.2013.08.019","article-title":"Design, synthesis, and structure\u2013activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents","volume":"69","author":"Tang","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2020.103797_b0205","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1016\/j.bmc.2009.05.042","article-title":"Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies","volume":"17","author":"Bora-Tatar","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0210","first-page":"625","article-title":"Preliminary screening of antineoplastic drugs","volume":"1","author":"Clarkson","year":"1965","journal-title":"Prog. Clin. Cancer"},{"key":"10.1016\/j.bioorg.2020.103797_b0215","first-page":"73","article-title":"Cytotoxic and antitumour activity of Berberin","volume":"17","author":"Sheeja","year":"1997","journal-title":"Amala Res Bull."},{"key":"10.1016\/j.bioorg.2020.103797_b0220","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0065-230X(08)60499-6","article-title":"The role of viruses in the production of cancer","volume":"2","author":"Oberling","year":"1954","journal-title":"Adv Cancer Res."},{"key":"10.1016\/j.bioorg.2020.103797_b0225","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/jama.296.12.1518","article-title":"An anniversary for cancer chemotherapy","volume":"296","author":"Hirsch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2020.103797_b0230","first-page":"95","article-title":"Heamatological complications of cancer chemotherapy","volume":"9","author":"Hogland","year":"1982","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2020.103797_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103664","article-title":"Synthesis, biological evaluation and molecular docking studies of new amides of 4-chlorothiocolchicine as anticancer agents","volume":"97","author":"Klejborowska","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0240","article-title":"Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents","volume":"98","author":"Abdelrasheed Allam","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0245","first-page":"1","article-title":"Detection of apoptosis using the BD Annexin V FITC assay on the BD FACSVerse TM system","author":"Jaimes","year":"2011","journal-title":"BD Biosci."},{"key":"10.1016\/j.bioorg.2020.103797_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0060017","article-title":"Cytometric analyses to distinguish death processes","volume":"6","author":"Gorczyca","year":"1999","journal-title":"Endocr. Relat. Cancer."},{"issue":"6749","key":"10.1016\/j.bioorg.2020.103797_b0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2020.103797_b0260","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2020.103797_b0265","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1021\/acs.jmedchem.7b00322","article-title":"Exploring derivatives of quinazoline alkaloid l-vasicine as cap groups in the design and biological mechanistic evaluation of novel antitumor histone deacetylase inhibitors","volume":"60","author":"Ahmad","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2020.103797_b0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1573406410666140507094954","volume":"11","author":"De Caro","year":"2015","journal-title":"Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2020.103797_b0275","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2174\/1871520614666140127113218","volume":"14","author":"Luna-Palencia","year":"2014","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2020.103797_b0280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2222-1808(12)60155-8","article-title":"Synthesis, characterization and biological evaluation of some glutathione inducing amino acid conjugates of valproic acid with reduced hepatotoxicity","volume":"2","author":"Sinha","year":"2012","journal-title":"Asian Pac. J. Trop. Dis."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819322412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819322412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:00:14Z","timestamp":1758614414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819322412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":56,"alternative-id":["S0045206819322412"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103797","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103797"}}